Spots Global Cancer Trial Database for Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer
Official Title: A Phase I/II Study of CR011-vcMMAE in Patients With Locally Advanced or Metastatic Breast Cancer
Study ID: NCT00704158
Conditions
Interventions
Study Description
Brief Summary: This study will evaluate the safety and tolerability of CR011-vcMMAE in patients with locally advanced and metastatic breast cancer. CR011-vcMMAE will be administered intravenously (IV) once every 3 weeks (q3w) to cohorts of 3-6 patients to confirm the maximum tolerated dose (MTD) in breast cancer patients. Once the MTD is confirmed, up to 25 patients with locally advanced or metastatic breast cancer will be enrolled into the Phase II portion of the trial to further evaluate the safety and efficacy of CR011-vcMMAE.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Florida Cancer Specialists, Ft. Myers, Florida, United States
Hematology Oncology Associates, Lake Worth, Florida, United States
Georgia Cancer Specialists, Atlanta, Georgia, United States
Cornell University, New York, New York, United States
Tennessee Oncology, Nashville, Tennessee, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
